- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03916250
Evaluation of Skin Irritation Potential With PF-06700841 Cream Formulation Using Negative Control in Adult Japanese Healthy Participants
May 23, 2019 updated by: Pfizer
A PHASE 1, SINGLE-CENTER, RANDOMIZED, VEHICLE AND WHITE PETROLATUM CONTROLLED, EVALUATOR BLINDED STUDY TO ASSESS THE SKIN IRRITATION POTENTIAL WITH A RANGE OF CONCENTRATIONS OF PF-06700841 CREAM IN ADULT JAPANESE HEALTHY PARTICIPANTS
This is a Phase 1, single center, randomized, vehicle and white petrolatum controlled, evaluator blinded study to assess the skin irritation potential with a range of concentrations of PF-06700841 cream including vehicle and empty patch with white petrolatum under occlusive conditions in adult Japanese healthy participants.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
20
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Osaka
-
Osaka-shi, Osaka, Japan, 532-0003
- Medical Corporation Heishinkai OPHAC Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years to 55 years (Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Male and female participants must be 20 to 55 years of age, inclusive, at the time of signing the informed consent document.
- Body mass index (BMI) of 17.5 to 25 kg/m2; and a total body weight >50 kg (110 lb).
Exclusion Criteria:
- Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological, or allergic disease.
- Participants who have any visible skin condition at the application site which, in the opinion of the investigative personnel, will interfere with the evaluation of the test site reaction.
- Participants who have psoriasis and/or active AD/eczema/urticaria.
- Participants who have a history of AD.
- Participants who have damaged skin in or around the test sites, including sunburn, excessively deep tans, uneven skin tones, tattoos, scars, excessive hair, numerous freckles, or other disfigurations of the test site.
- History of known or suspected intolerance to any of the ingredients of the investigational products, adhesive tape/plaster, or the test patches.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: PF-06700841 cream 0%
All participants will have 6 application sites where 6 patches of investigational products will be completely randomly assigned, for the purpose of determining irritation potential
|
PF-06700841 will be applied topically
Other Names:
|
Experimental: PF-06700841 cream 0.1%
All participants will have 6 application sites where 6 patches of investigational products will be completely randomly assigned, for the purpose of determining irritation potential
|
PF-06700841 will be applied topically
Other Names:
|
Experimental: PF-06700841 cream 0.3%
All participants will have 6 application sites where 6 patches of investigational products will be completely randomly assigned, for the purpose of determining irritation potential
|
PF-06700841 will be applied topically
Other Names:
|
Experimental: PF-06700841 cream 1%
All participants will have 6 application sites where 6 patches of investigational products will be completely randomly assigned, for the purpose of determining irritation potential
|
PF-06700841 will be applied topically
Other Names:
|
Experimental: PF-06700841 cream 3%
All participants will have 6 application sites where 6 patches of investigational products will be completely randomly assigned, for the purpose of determining irritation potential
|
PF-06700841 will be applied topically
Other Names:
|
Experimental: White petrolatum
All participants will have 6 application sites where 6 patches of investigational products will be completely randomly assigned, for the purpose of determining irritation potential
|
White petrolatum will be applied topically
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The proportion of participants who have skin irritation grade equal to or greater than two plus (++) up to Day 4
Time Frame: Up to Day 4
|
Skin irritation grade is defined as following: no reaction (-); slight erythema (+-); erythema (+); erythema + edema, papules (++); erythema + edema + papules + vesicles (small blisters) (+++) ; large blisters (++++)
|
Up to Day 4
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The proportion of participants who have skin irritation grade equal to or greater than two plus (++) on each assessment day (Day 3 and Day 4)
Time Frame: Day 3 and Day 4
|
Skin irritation grade is defined as following: no reaction (-); slight erythema (+-); erythema (+); erythema + edema, papules (++); erythema + edema + papules + vesicles (small blisters) (+++) ; large blisters (++++)
|
Day 3 and Day 4
|
The number of the maximum skin irritation score reported up to Day 4 by treatment
Time Frame: Up to Day 4
|
Skin irritation score is defined as following: no reaction (0); slight erythema (0.5); erythema (1); erythema + edema, papules (2); erythema + edema + papules + vesicles (small blisters) (3) ; large blisters (4)
|
Up to Day 4
|
The percentage of the maximum skin irritation score reported up to Day 4 by treatment
Time Frame: Up to Day 4
|
Skin irritation score is defined as following: no reaction (0); slight erythema (0.5); erythema (1); erythema + edema, papules (2); erythema + edema + papules + vesicles (small blisters) (3) ; large blisters (4)
|
Up to Day 4
|
The number of each skin irritation score reported by treatment on each assessment day
Time Frame: Day 3 and Day 4
|
Skin irritation score is defined as following: no reaction (0); slight erythema (0.5); erythema (1); erythema + edema, papules (2); erythema + edema + papules + vesicles (small blisters) (3) ; large blisters (4)
|
Day 3 and Day 4
|
The percentage of each skin irritation score reported by treatment on each assessment day
Time Frame: Day 3 and Day 4
|
Skin irritation score is defined as following: no reaction (0); slight erythema (0.5); erythema (1); erythema + edema, papules (2); erythema + edema + papules + vesicles (small blisters) (3) ; large blisters (4)
|
Day 3 and Day 4
|
Number of Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs)
Time Frame: Baseline up to Day 35
|
Baseline up to Day 35
|
|
Number of Participants Discontinuation Due to AEs
Time Frame: Baseline up to Day 35
|
Baseline up to Day 35
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 23, 2019
Primary Completion (Actual)
April 15, 2019
Study Completion (Actual)
May 12, 2019
Study Registration Dates
First Submitted
March 20, 2019
First Submitted That Met QC Criteria
April 12, 2019
First Posted (Actual)
April 16, 2019
Study Record Updates
Last Update Posted (Actual)
May 24, 2019
Last Update Submitted That Met QC Criteria
May 23, 2019
Last Verified
May 1, 2019
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- B7931029
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
IPD Plan Description
Pfizer will provide access to individual de-identified participant data and related study documents (e.g.
protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions.
Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
-
King's College LondonUniversity of ReadingCompletedHealthy | Healthy AgingUnited Kingdom
Clinical Trials on PF-06700841 cream
-
PfizerCompletedHealthy ParticipantsUnited States
-
PfizerCompletedHealthy Male SubjectsNetherlands
-
PfizerCompleted
-
PfizerCompletedSystemic Lupus ErythematosusSpain, United States, Taiwan, Belgium, Czechia, Japan, Hungary, Germany, United Kingdom, China, France, Australia, Bulgaria, Hong Kong, Korea, Republic of, Colombia, Argentina, Canada, Greece, Italy, Mexico, Poland, Portugal, Romania, S... and more
-
PfizerCompletedHealthy ParticipantsBelgium
-
PfizerCompletedCrohn's DiseaseUnited States, Spain, Lebanon, Australia, Russian Federation, Korea, Republic of, Tunisia, Italy, Poland, Belgium, Austria, Germany, Saudi Arabia, Czechia, Hungary, Switzerland, Turkey, Slovakia, Ukraine, Georgia, Bosnia and Herzegovina and more
-
PfizerCompletedUlcerative ColitisUnited States, Spain, Israel, Korea, Republic of, Russian Federation, Turkey, Czechia, Hungary, Italy, Poland, Bulgaria, Denmark, Germany, Serbia, Austria, Slovakia, Ukraine, Georgia, Romania
-
PfizerCompletedAlopecia AreataUnited States, Canada, Australia
-
PfizerCompletedAcne InversaUnited States, Australia, Canada
-
PfizerCompletedActive Non-segmental VitiligoSpain, United States, Korea, Republic of, Taiwan, Canada, Australia, Germany, Japan, Belgium, Italy